🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

17,82 USD

Máx. histórico

178,74

2145 días

Split 1:6 del 12/07/2012

Caída desde máximo

-90,03%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+1,42%

Cierre anterior

17,57

Rango de hoy

17,52 – 18,77

Volumen hoy

2.596.193

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 19 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
08/02/2011 12,72 13,14 12,60 12,66 -0,94% 4,25% 159.917
07/02/2011 12,48 12,96 12,48 12,78 +2,40% 3,85% 178.950
04/02/2011 12,84 12,84 12,36 12,48 -2,80% 3,74% 157.383
03/02/2011 12,36 12,84 12,36 12,84 +3,88% 3,88% 161.783
02/02/2011 12,72 12,84 12,12 12,36 -1,90% 5,66% 174.450
01/02/2011 13,08 13,08 12,42 12,60 -3,23% 5,05% 216.300
31/01/2011 12,78 13,56 12,48 13,02 +2,36% 8,45% 246.483
28/01/2011 13,44 13,50 12,60 12,72 -5,78% 6,70% 299.467
27/01/2011 13,38 13,68 13,26 13,50 +0,90% 3,14% 242.400
26/01/2011 13,38 13,68 13,20 13,38 +0,90% 3,59% 187.233
25/01/2011 13,74 13,80 13,26 13,26 -3,91% 3,93% 159.750
24/01/2011 14,28 14,70 13,50 13,80 -2,95% 8,40% 244.067
21/01/2011 14,04 14,40 13,80 14,22 +2,60% 4,27% 267.367
20/01/2011 13,32 14,40 13,20 13,86 +3,13% 9,01% 250.450
19/01/2011 14,58 14,58 13,32 13,44 -7,82% 8,64% 363.117
18/01/2011 15,00 15,00 14,46 14,58 -2,41% 3,60% 155.467
14/01/2011 14,46 14,94 13,98 14,94 +3,75% 6,64% 276.633
13/01/2011 15,42 15,60 14,22 14,40 -5,51% 8,95% 528.600
12/01/2011 15,48 15,60 14,58 15,24 -1,55% 6,59% 337.067
11/01/2011 15,48 16,44 15,12 15,48 +0,00% 8,53% 480.567
10/01/2011 14,28 15,60 14,10 15,48 +6,17% 10,50% 625.817
07/01/2011 13,08 14,76 13,02 14,58 +11,98% 13,30% 635.283
06/01/2011 13,02 13,08 12,84 13,02 +0,46% 1,84% 166.000
05/01/2011 12,60 13,02 12,60 12,96 +1,41% 3,33% 120.183
04/01/2011 13,14 13,14 12,66 12,78 -1,84% 3,65% 157.883
03/01/2011 12,90 13,14 12,72 13,02 +2,36% 3,26% 176.817
31/12/2010 12,96 13,08 12,60 12,72 -1,85% 3,70% 148.183
30/12/2010 12,60 13,20 12,54 12,96 +1,89% 5,24% 205.150
29/12/2010 12,42 12,90 12,24 12,72 +2,42% 5,31% 254.533
28/12/2010 12,36 12,60 12,36 12,42 +0,00% 1,94% 78.050